US investors’ use of equity derivatives grows

Greenwich Associates says that US institutional investors are increasing their use of equity derivatives overall, though their use of some complex products is waning.

According to the Connecticut-based consultancy, single-stock listed options, vanilla over-the-counter (OTC) options, exchange traded funds (ETFs), and equity swaps are coming into more widespread use. ETFs, for example, are now used by 75% of the investors it recently surveyed - 18% more than two years ago.

John Colon, a consultant at Connecticut-based Greenwich Associates said the growing use of equity derivatives across various strategies suggests a rising number of institutions are using the instruments as substitutes for cash equity trading.

Investors are opting for derivatives because of the ease with which the instruments help them gain leverage and anonymity, alongside beneficial tax treatment, Greenwich said.

However, US institutional investors’ use of some complex products, such as variance swaps and fund-linked and index-based products, has dropped by 20% during the past year. In contrast, European institutional investors have increased their use of tailored OTC, securitised, and hybrid derivatives by 15% over the same period.

This growth has been largely driven off the back of the popularity of structured products with the European retail and high-net worth (HNW) clients of dealers in Europe. According to Greenwich, only 5% of US dealers on-sell structured products to their retail and HNW client base.

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@risk.net or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact info@risk.net to find out more.

Most read articles loading...

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here